Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - ORAMED PHARMACEUTICALS INC.exhibit_99-1.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION 
Washington, D.C. 20549

_____________________
 
FORM 8-K
_____________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 8, 2011
_____________________

ORAMED PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
 
Delaware
(State or other jurisdiction
of incorporation)
000-50298
(Commission File Number)
98-0376008
(IRS Employer
Identification No.)

Hi-Tech Park 2/5 Givat Ram
PO Box 39098
Jerusalem, Israel 91390
 (Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: 972-2-566-0001

_____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
 
ITEM 8.01   OTHER EVENTS
 
On September 8, 2011, Oramed Pharmaceuticals Inc. issued a press release announcing that Roy Eldor, M.D., the Director of Medical Affairs at Oramed, is scheduled to present at the Rodman & Renshaw 13th Annual Global Investment Conference in the Israel track. The conference will be held at the Waldorf Astoria Hotel in New York City. Dr. Eldor is scheduled to speak on Thursday September 13, 2011 at1:35 p.m. DST in the Sutton Suite. He will discuss Oramed's strategic initiatives, updates and product pipeline.
 
A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.
 
ITEM 9.01   FINANCIAL STATEMENTS AND EXHIBITS.

(d) 
Exhibits
 
Exhibit
Number
Description
 
     
99.1
Press Release dated September 8, 2011
 

 
 

 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
ORAMED PHARMACEUTICALS INC.
 
Dated: September 12, 2011
     
 
By: 
 /s/ Nadav Kidron 
 
   
 Nadav Kidron 
 
   
 President, CEO and Director 
 

 
 

 

Exhibit Index

Exhibit
Number
Description
   
99.1
Press Release dated September 8, 2011